A multicentre, randomised, double-blind, placebo-controlled study of the effects of KW-3902 Injectable Emulsion on heart failure signs and symptoms and renal function in subjects with acute heart failure syndrome and renal impairment who are hospitalised for volume overload and require intravenous diuretic therapy The main objective of this study is to evaluate the effect of KW-3902IV in addition to IV loop diuretic therapy on heart failure signs and symptoms, persistent renal function, morbidity and mortality,...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Multicenter, Randomized, Double-Blind, "Factorial" Design Study to Evaluate the Lipid-Altering Efficacy and Safety of MK-0524B Combination Tablet in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia In patients with primary hypercholesterolemia or mixed hyperlipidemia, evaluate: The LDL-C lowering efficacy of MK-0524B 2g (pooled across simvastatin doses of 20 and 40 mg) compared to MK-0524A 2g.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Multicenter, Randomized, Double-Blind Study of MK-0431 in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control Main objective : In patients with type 2 diabetes mellitus with inadequate glycemic control on diet and exercise: (1) After 18 weeks, to assess the effect of treatment with MK-0431 compared with ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A phase IIb study of ridaforolimus, dalotzumab and exemestane in combination in advanced breast cancer The primary objective of the study is to evaluate the progression free survival (PFS) for the triplet combination of ridaforolimus, dalotuzumab and exemestane (R/D/E) compared to the combination of ri...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A phase III, double-blind, placebo-controlled, randomised trial to determine the efficacy and safety of a dose range of 50 to 100 mg/day of safinamide, as add-on therapy, in subjects with idiopathic Parkinson’s Disease with motor fluctuations, treated with a stable dose of levodopa and who may be receiving concomitant treatment with stable doses of a dopamine agonist, an anticholinergic and/or amantadine The objectives of this trial are to evaluate the efficacy and safety of a dose range of safinamide 50-100 mg p.o. q.a.m., compared to placebo as add-on therapy in subjects with idiopathic Parkinson’s ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Étude MK-3475-587 : Étude d'extension de phase 3 multicentrique, ouverte évaluant la sécurité et l'efficacité à long terme du pembrolizumab chez des patients ayant des tumeurs avancées traitées ou faisant l'objet d'un suivi dans le cadre d'un essai clinique. Les tumeurs solides sont l’ensemble des cancers qui se développent dans n’importe quel tissu : peau, muqueuses, os, organes, etc. Ce sont les plus fréquentes puisqu’elles représentent 90% des cancers ...

• Pays France
• Organes Tumeurs solides
• Spécialités Thérapies Ciblées, Chimiothérapie

A study to evaluate the safety and efficacy of the addition of a new drug (MK-3102) in patients with Type 2 Diabetes between the age of 18 and 44 years old, who are not taking any medications 1. To assess the effect of treatment with MK-3102 compared with placebo on A1C. 2. To assess the safety and tolerability of MK-3102.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of MK-0431 Monotherapy in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control Main objective : In patients with type 2 diabetes mellitus with inadequate glycemic control on diet and exercise: (1) After 24 weeks, to assess the effect of treatment with MK-0431 compared with plac...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Randomized, Double-Blind, Active-Controlled, Multicenter Study to Assess the LDL-C Lowering of Switching to a Combination tablet Ezetimibe/Simvastatin (10mg/20mg) compared to Rosuvastatin 10mg in patients with primary hypercholesterolemia and high cardiovascular risk and not adequately controlled with a prior statin treatment. (IN-CROSS) In patients with primary hypercholesterolemia and high cardiovascular risk treated with a statin and with elevated LDL-Cholesterol at baseline to assess the additional LDL-C percentage reduction by sw...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

An Open-label, One-arm, Proof of Concept Trial to Evaluate the Safety of ATX-MS-1467 (MSC2358825A) and its Effect on Immune Tolerance in Subjects with Relapsing Multiple Sclerosis The primary objective of the trial is to evaluate the effects of ATX-MS-1467 administered intradermally, titrated to a dose of 800 μg every 2 weeks (biweekly), for a total period of 20 weeks on 1.5T M...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune